{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for ethanolamine root_notes_note in Note (approximate match)
Status:
Possibly Marketed Outside US
Source:
M017
(2017)
Source URL:
First approved in 2013
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2012)
Source URL:
First approved in 2012
Source:
21 CFR 333D
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2015)
Source URL:
First approved in 2009
Source:
M021
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2007)
Source URL:
First approved in 2007
Source:
21 CFR 333D
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333C
(2005)
Source URL:
First approved in 2002
Source:
21 CFR 358H
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2019)
Source URL:
First approved in 1997
Source:
21 CFR 333E
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M015
(2022)
Source URL:
First approved in 1983
Source:
NDA018723
Source URL:
Class:
MIXTURE
Status:
Investigational
Source:
Burns. Sep 2006;32(6):698-705.: Phase 3 Human clinical trial Completed N/A
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
NCT00348764: Phase 3 Interventional Completed Venous Insufficiency
(2004)
Source URL:
Class:
POLYMER
Status:
Other
Class:
POLYMER
